

Bibliographie

Originalarbeiten

1. **Herrmann T**, Schindler D, Tabe H, Onodera O, Igarashi S, Polack A, Zehnpfennig D, Tsuji S. Molecular cloning, structural organization, sequence, chromosomal assignment, and expression of the mouse alpha-N-acetylgalactosaminidase gene. *Gene* 1998; 211: 205-214.
2. Riedel HD, Muckenthaler MU, Gehrke SG, Mohr I, Brennan K, **Herrmann T**, Fitscher BA, Hentze MW, Stremmel W. HFE downregulates iron uptake from transferrin and induces iron-regulatory protein activity in stably transfected cells. *Blood* 1999; 94: 3915-3921.
3. Fitscher BA, Eehalt R, Jochims C, Pohl J, **Herrmann T**, Stremmel W. Functional and histochemical analysis of MDR3 P-glycoprotein in a tetracycline-controlled gene expression system. *Eur. J. Med. Res.* 2000; 5: 517-522.
4. **Herrmann T**, Buchkremer F, Gosch I, Hall AM, Bernlohr DA, Stremmel W. Mouse fatty acid transport protein 4 (FATP4): Characterization of the gene and functional assessment as a very long chain acyl-CoA synthetase. *Gene* 2001; 270: 31-40.
5. Gehrke SG, Kulaksiz H, **Herrmann T**, Riedel HD, Bents K, Veltkamp C, Stremmel W. Expression of hepcidin in hereditary hemochromatosis: evidence for a regulation in response to serum transferrin saturation and non-transferrin-bound iron. *Blood* 2003; 102: 371-376.
6. Gehrke SG, Riedel HD, **Herrmann T**, Hadaschik B, Bents K, Veltkamp C, Stremmel W. UbcH5A, a member of human E2 ubiquitin-conjugating enzymes, is closely related to SFT, a stimulator of iron transport, and is up-regulated in hereditary hemochromatosis. *Blood* 2003; 101: 3288-3293.
7. **Herrmann T**, van der Hoeven F, Gröne H-J, Stewart AF, Langbein L, Kaiser I, Liebisch G, Gosch I, Buchkremer F, Drobnik W, Schmitz G, Stremmel W. Mice with targeted disruption of the fatty acid transport protein 4 (Fatp 4, Slc27a4) gene show features of lethal restrictive dermopathy. *J. Cell Biol.* 2003; 161: 1105-1115.
8. Rost D, **Herrmann T**, Sauer P, Schmidts H-L, Stieger B, Meier PJ, Stremmel W, Stiehl A. Regulation of rat organic anion transporters in bile salt-induced cholestatic hepatitis: Effect of ursodeoxycholate. *Hepatology* 2003; 38: 187-195.
9. **Herrmann T**, Muckenthaler M, van der Hoeven F, Brennan K, Gehrke SG, Hubert N, Sergi C, Gröne H-J, Kaiser I, Gosch I, Volkmann M, Riedel H-D, Hentze MW, Stewart AF, Stremmel W. Iron overload in adult Hfe-deficient mice independent of changes in the steady state expression of the duodenal iron transporters DMT1 and Ireg1/ferroportin. *J. Mol. Med.* 2004; 82: 39-48.
10. Testa G, Schaft J, van der Hoeven F, Glaser S, Anastassiadis K, Zhang Y, **Herrmann T**, Stremmel W, Stewart AF. A reliable lacZ expression reporter cassette for multipurpose, knockout-first alleles. *Genesis* 2004; 38: 151-158.
11. Gehrke SG*, **Herrmann T***, Kulaksiz H, Merle U, Bents K, Kaiser I, Riedel H-D, Stremmel W. Iron stores modulate hepatic hepcidin expression by an HFE-independent pathway. *Digestion* 2005; 72: 25-32. * equal contribution.
12. Gehrke S, Pietrangelo A, Kascak M, Braner A, Eisold M, Kulaksiz H, **Herrmann T**, Hebling U, Bents K, Gugler R, Stremmel W. HJV gene mutations in European patients with juvenile hemochromatosis. *Clin. Genet.* 2005; 67: 425-428.
13. Hall AM, Wiczler BM, **Herrmann T**, Stremmel W, Bernlohr DA. Enzymatic properties of purified murine fatty acid transport protein 4 and analysis of Acyl CoA synthetase activities in tissues from FATP4 null mice. *J. Biol. Chem.* 2005; 280: 11948-11954.
14. **Herrmann T**, Gröne H-J, Langbein L, Kaiser I, Gosch I, Bennemann U, Metzger D, Chambon P, Stewart AF, Stremmel W. Disturbed epidermal structure in mice with temporally controlled Fatp4 deficiency. *J. Invest. Dermatol.* 2005; 125: 1228-1235.

15. Knaebel HP, Marten A, Schmidt J, Hoffmann K, Seiler C, Lindel K, Schmitz-Winnenthal H, Fritz S, **Herrmann T**, Goldschmidt H, Krempien R, Mansmann U, Debus J, Diehl V, Buchler MW. Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma - CapRI: study protocol. *BMC Cancer* 2005, 5: 37.
16. Kasper B, Kallinowski B, **Herrmann T**, Lehnert T, Mechtersheimer G, Geer T, Ho AD, Egerer G. Treatment of gastrointestinal stromal tumor (GIST) – a retrospective single-centre experience in Heidelberg. *Dig. Dis.* 2006; 24: 207-211.
17. Milger K, **Herrmann T**, Becker C, Gotthardt D, Zickwolf J, Eehalt R, Watkins P, Stremmel W, Füllekrug J. Cellular uptake of fatty acids driven by the ER localized acyl-CoA synthetase FATP4. *J. Cell Sci.* 2006; 119: 4678-4688.
18. Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schäfer M, Schilling T, Haufe S, **Herrmann T**, Haberkorn U. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. *Eur. J. Nucl. Med. Mol. Imaging* 2007; 34: 1617-1626.
19. Ciuleanu T, Diculescu M, Hoepffner NM, Trojan J, Sailer V, Zalupski M, **Herrmann T**, Roth A, Chick J, Brock K, Albert D, Philip PA. A randomised phase II study of OSI-7904L versus 5-fluorouracil (FU)/leucovorin (LV) as first-line treatment in patients with advanced biliary cancers. *Invest. New Drugs* 2007; 25: 385-390.
20. Elsing C, Gosch I, Hennings JC, Hübner CA, **Herrmann T**. Mechanisms of hypotonic inhibition of the sodium, proton exchanger type 1 (NHE1) in a biliary epithelial cell line (Mz-Cha-1). *Acta Physiol. (Oxf.)* 2007; 190: 199-208.
21. Elsing C, Harenberg S, Stremmel W, **Herrmann T**. Serum levels of soluble Fas, nitric oxide and cytokines in acute decompensated cirrhotic patients. *World J. Gastroenterol.* 2007; 13: 421-425.
22. Fein E, Merle U, Eehalt R, **Herrmann T**, Kulaksiz H. Regulation of hepcidin in HepG2 and RINm5F cells. *Peptides* 2007; 28: 951-957.
23. Herrmann C, Abel U, Stremmel W, Jaeger D, **Herrmann T**. Short time to progression under first-line chemotherapy is a negative prognostic factor for time to progression and residual survival under second-line chemotherapy in advanced pancreatic cancer. *Oncology* 2007; 73: 335-339.
24. Vujic Spasic M*, Kiss J*, **Herrmann T***, Hess R, Stolte J, Galy B, Rathkolb B, Wolf E, Stremmel W, Hentze MW, Muckenthaler MU. Physiological systemic iron metabolism in mice deficient for duodenal Hfe. *Blood* 2007; 109: 4511-4517. * equal contribution.
25. Arnold D, Höhler T, Dittrich C, Lordick F, Seufferlein T, Riemann J, Wöll E, **Herrmann T**, Zubel A, Schmoll HJ. Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. *Ann. Oncol.* 2008; 19: 1442-1449.
26. Eehalt R, Sparla R, **Herrmann T**, Kulaksiz H, Füllekrug J, Stremmel W. Uptake of long chain fatty acids is regulated by dynamic interaction of FAT/CD36 with cholesterol/sphingolipid enriched microdomains (lipid rafts). *BMC Cell Biol.* 2008; 9: 45.
27. Halama N, Herrmann C, Jaeger D, **Herrmann T**. Treatment with cetuximab, bevacizumab and irinotecan in heavily pretreated patients with metastasized colorectal cancer. *Anticancer Res.* 2008; 28: 4111-4115.
28. Perez D*, **Herrmann T***, Jungbluth AA, Samartzis P, Spagnoli G, Demartines N, Clavien P-A, Marino S, Seifert B, Jager D. Cancer Testis Antigen Expression in Gastrointestinal Stromal Tumors: New Markers for Early Recurrence. *Int. J. Cancer* 2008; 123: 1551-1555. * equal contribution.
29. Vujčić Spasić M*, Kiss J*, **Herrmann T***, Galy B, Martinache S, Stolte J, Gröne H-J, Stremmel W, Hentze MW, Muckenthaler MU. Hfe acts in hepatocytes to prevent hemochromatosis. *Cell Metab.* 2008; 7: 173-178. * equal contribution.

30. Elsing C, Stremmel W, Grenda U, **Herrmann T**. Gamma-hydroxybutyric acid versus clomethiazole for the treatment of alcohol withdrawal syndrome in a medical intensive care unit: an open, single-center randomized study. *Am. J. Drug Alcohol Abuse* 2009; 35: 189-192.
31. Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J, Konopke R, Stroszczyński C, Liersch T, Ockert D, **Herrmann T**, Goekkurt E, Parisi F, Köhne CH. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. *Lancet Oncol.* 2010; 11: 38-47.
32. Merle U, Tuma S, **Herrmann T**, Muntean V, Volkmann M, Gehrke SG, Stremmel W. Evidence for a critical role of ceruloplasmin oxidase activity in iron metabolism of Wilson disease gene knockout mice. *J. Gastroenterol. Hepatol.* 2010; 25: 1144-1150.
33. Elsing C, Voss A, **Herrmann T**, Kaiser I, Huebner CA, Schlenker T. Oxidative stress reduces Na⁺/H⁺ exchange (NHE) activity in a biliary epithelial cancer cell line (Mz-Cha-1). *Anticancer Res.* 2011; 31: 459-465.
34. Lenz LS, Marx J, Chamulitrat W, Kaiser I, Gröne HJ, Liebisch G, Schmitz G, Elsing C, Straub BK, Füllekrug J, Stremmel W, **Herrmann T**. Adipocyte-specific inactivation of the acyl-CoA-synthetase fatty acid transport protein 4 (Fatp4) in mice causes adipose hypertrophy and alterations in metabolism of complex lipids under high-fat diet. *J. Biol. Chem.* 2011; 286: 35578-35587.
35. Pfeiffenberger J, Gotthardt D, **Herrmann T**, Seeßle J, Merle U, Schirmacher P, Stremmel W, Weiss KH. Iron metabolism and the role of HFE gene polymorphisms in Wilson disease. *Liver Int.* 2012; 32: 165-170.
36. Schmidt J, Abel U, Debus J, Harig S, Hoffmann K, **Herrmann T**, Bartsch D, Klein J, Mansmann U, Jäger D, Capussotti L, Kunz R, Büchler MW. Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma. *J. Clin. Oncol.* 2012; 30: 4077-4083.
37. Elsing C, Herrmann C, Hannig CV, Stremmel W, Jäger D, **Herrmann T**. Sequential chemotherapies for advanced gastric cancer: a retrospective analysis of 111 patients. *Oncology* 2013; 85: 262-268.
38. Malka D, Cervera P, Foulon S, Trarbach T, de la Fouchardière C, Boucher E, Fartoux L, Faivre S, Blanc JF, Viret F, Assenat E, Seufferlein T, **Herrmann T**, Grenier J, Hammel P, Dollinger M, André T, Hahn P, Heinemann V, Rousseau V, Ducreux M, Pignon JP, Wendum D, Rosmorduc O, Greten TF. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. *Lancet Oncol.* 2014; 15: 819-828.
39. Haag GM, **Herrmann T**, Jaeger D, Stremmel W, Schemmer P, Sauer P, Gotthardt DN. Outcomes and risk factors for cancer patients undergoing endoscopic intervention of malignant biliary obstruction. *BMC Gastroenterol.* 2015;15: 171-177.
40. Halama N, Zoernig I, Berthel A, Kahlert C, Klupp F, Suarez-Carmona M, Suetterlin T, Brand K, Krauss J, Lasitschka F, Lerchl T, Luckner-Minden C, Ulrich A, Koch M, Weitz J, Schneider M, Buechler M W, Zitvogel L, **Herrmann T**, Benner A, Kunz C, Luecke S, Springfield C, Grabe N, Falk CS, Jaeger D. Tumoral immune cell exploitation in colorectal cancer liver metastases can be targeted effectively by anti-CCR5 therapy in cancer patients. *Cancer Cell* 2016; 29: 587-601.
41. Loske G, Liedke M, Schlöricke E, **Herrmann T**, Rucktaeschel F. Endoscopic negative-pressure therapy for duodenal leakage using new open-pore film and polyurethane foam drains with the pull-through technique. *Endoscopy* 2017; 49: E300-E302.

Fallberichte

1. Buchkremer F, **Herrmann T**, Stremmel W. Mild respiratory distress after wireless capsule endoscopy. *Gut* 2004; 53: 472.
2. Elsing C, Placke J, **Herrmann T**. Alcohol binging causes peliosis hepatis during azathioprine therapy in Crohn's disease. *World J. Gastroenterol.* 2007; 13: 4646-4648.
3. Elsing C, Stremmel W, **Herrmann T**. Spontaneous remission of autoimmune hepatitis in pregnancy and postpartum flare. *Indian J. Gastroenterol.* 2007; 26: 104.

Übersichtsarbeiten

1. **Herrmann T**, Riedel HD, Gehrke SG, Stremmel W. Hämochromatose - Pathogenese, Klinik und Therapie einer der häufigsten Erbkrankheiten. *Verdauungskrankheiten* 1998; 16: 214-222.
2. Gehrke SG, Henrich I, Mytilineos J, Riedel HD, **Herrmann T**, Kallinowski B, Stremmel W. Mutationen des Hämochromatosegens HFE – Diagnostischer Einsatz und klinische Relevanz bei Lebererkrankungen. *Verdauungskrankheiten* 1998; 16: 223-229.
3. **Herrmann T**, Smolarek C, Gehrke S, Schäfer M, Stremmel W. Hämochromatose und Morbus Wilson. *Der Internist* 1999; 40: 513-521.
4. Stremmel W, Pohl J, Ring A, **Herrmann T**. A new concept of cellular uptake and intracellular trafficking of long-chain fatty acids. *Lipids* 2001; 36: 981-989.
5. Stremmel W, Blechacz B, **Herrmann T**, Rost D, Mueller S. Die Therapie der alkoholischen und nichtalkoholischen Steatosis hepatis. *Der Internist* 2001; 42: 1641-1650.
6. Pohl J, Ring A, Eehalt R, **Herrmann T**, Stremmel W. New concepts of cellular fatty acid uptake: role of fatty acid transport proteins and of caveolae. *Proc. Nutr. Soc.* 2004; 63: 259-262.
7. Pohl J, Ring A, **Herrmann T**, Stremmel W. Role of FATP in parenchymal cell fatty acid uptake. *Biochim. Biophys. Acta* 2004; 1686: 1-6.
8. Eehalt R, Fullekrug J, Pohl J, Ring A, **Herrmann T**, Stremmel W. Translocation of long chain fatty acids across the plasma membrane - lipid rafts and fatty acid transport proteins. *Mol. Cell. Biochem.* 2006; 284: 135-140.
9. **Herrmann T**, Herrmann C. Perioperative Chemotherapie von Lebermetastasen – Hepatotoxizität und Auswirkung auf die perioperative Morbidität. *Journal Onkologie* 2007; 6: 294-298.
10. Stremmel W, Karner M, Manzhali E, Gilles W, **Herrmann T**, Merle U. Liver and iron metabolism – a comprehensive hypothesis for the pathogenesis of genetic hemochromatosis. *Z. Gastroenterol.* 2007; 45: 71-75.

Buchbeiträge

1. Stremmel W, Smolarek C, **Herrmann T**, Gehrke S. Störungen des Kupfer- und Eisenstoffwechsels der Leber. In: Biesalski HK, Köhrle J, Schümann K (Hrsg.). *Vitamine, Spurenelemente und Mineralstoffe*. S. 641-650. Georg Thieme Verlag, Stuttgart 2002.
2. Niederau C, **Herrmann T**, Strohmeyer G. Hereditäre Hämochromatose. In: Strohmeyer G, Stremmel W, Niederau C (Hrsg.). *Angeborene Stoffwechselerkrankungen*. S. 121-156. Ecomed Verlagsgesellschaft, Landsberg/Lech 2002.